GSA Capital Partners LLP Lowers Position in Personalis, Inc. (NASDAQ:PSNL)

GSA Capital Partners LLP cut its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 70.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 124,082 shares of the company’s stock after selling 302,794 shares during the quarter. GSA Capital Partners LLP owned about 0.23% of Personalis worth $668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of PSNL. ARK Investment Management LLC lifted its stake in Personalis by 11.4% during the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after acquiring an additional 723,637 shares in the last quarter. Semanteon Capital Management LP acquired a new position in Personalis during the 3rd quarter worth about $375,000. International Assets Investment Management LLC lifted its stake in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after acquiring an additional 17,082 shares in the last quarter. nVerses Capital LLC acquired a new position in Personalis during the 3rd quarter worth about $40,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after acquiring an additional 4,504 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $7.25 target price on shares of Personalis in a research note on Thursday, November 7th. BTIG Research increased their price target on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, HC Wainwright increased their price target on Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 19th.

Personalis Price Performance

PSNL stock opened at $3.59 on Tuesday. The firm has a market capitalization of $253.63 million, a P/E ratio of -2.14 and a beta of 1.94. The business’s 50-day moving average is $5.03 and its two-hundred day moving average is $3.49. Personalis, Inc. has a 1 year low of $1.12 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $25.71 million during the quarter, compared to analysts’ expectations of $20.67 million. During the same quarter in the previous year, the company posted ($0.51) EPS. On average, analysts expect that Personalis, Inc. will post -1.33 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.